Trial Profile
A randomized, single blinded trial to evaluate the efficacy of Imiquimod in women with residual/recurrent Cervical Intraepithelial Neoplasia (CIN) after previous treatment
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- Acronyms TopIC-2
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 05 Feb 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 05 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.